Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06939751 · ClinicalTrials.gov registry record
OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels
A clinical trial of Graft Rejection and Cardiac Failure, sponsored by Inova Health Care Services.
- Recruiting
- Registry status
- 250
- Enrollment target
- 5
- Study locations
NCT06939751: Recruiting study of Graft Rejection and Cardiac Failure, sponsored by Inova Health Care Services.
NCT06939751 is a study of Graft Rejection and Cardiac Failure that is actively recruiting participants, run by Inova Health Care Services. The registered enrollment target is 250 participants, below the 438-participant average among 5 other Graft Rejection trials with a reported enrollment target (43% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06939751, a study of Graft Rejection and Cardiac Failure, is actively recruiting participants, sponsored by Inova Health Care Services.
- RECRUITING
- Registry status
- 250 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study aims to develop and refine a microRNA (miR) biomarker panel that can be used to phenotype net immune state after heart transplantation using circulating miRs (associated with drug doses and levels). These miRs will be used to characterize the overall immune state in adult heart transplant patients and predict patients that will go on to develop infection and rejection. MicroRNAs (miRs) are small, non-coding RNA molecules that regulate gene expression and serve as molecular biomarkers found in the circulation.
Primary Outcome
A time-to-event analysis will be performed to identify specific circulating microRNAs (miRs) that predict the risk of infection in heart transplant recipients. Infections are defined as any bacterial, viral, fungal, or opportunistic infection leading to: 1) hospitalization, 2) prescription of antimicrobial therapy, or 3) reduction in immunosuppression
Conditions Studied
Study Locations (5)
California
- Stanford University - Palo Alto
South Carolina
- Medical University of South Carolina - Charleston
Tennessee
- Vanderbilt University - Nashville
Texas
- Baylor University Medical Center - Dallas
Virginia
- Inova Health System - Falls Church
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2025-10-28 |
| Est. Completion | 2032-01-01 |
What NCT06939751 shows while recruiting
NCT06939751 is an observational study that tracks outcomes without assigning an intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 438-participant average among 5 other Graft Rejection trials with a reported enrollment target (43% lower).
The record links to 2 conditions, with Graft Rejection appearing as the primary indexed condition, and to 0 interventions.
NCT06939751 lists 5 locations in 5 states (California, South Carolina, Tennessee).
Frequently Asked Questions
What is clinical trial NCT06939751 about?
NCT06939751 is a clinical study titled "OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels". This study aims to develop and refine a microRNA (miR) biomarker panel that can be used to phenotype net immune state after heart transplantation using circulating miRs (associated with drug doses and levels). These miRs will be used to characterize the overall immune state in adult heart transplant...
What is the current status of trial NCT06939751?
This trial is currently recruiting. The enrollment target is 250 participants. The study started on 2025-10-28. Estimated completion is 2032-01-01.
What conditions does trial NCT06939751 study?
This clinical trial studies the following conditions: Graft Rejection, Cardiac Failure.
Who is sponsoring clinical trial NCT06939751?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06939751 being conducted?
This trial has 5 study locations across California, South Carolina, Tennessee, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft Rejection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs
RECRUITING
-
Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
RECRUITING
-
Cardiac Allograft Rejection Gene Expression Observational (CARGO) II STUDY
COMPLETED
-
HLA-Identical Sibling Renal Transplant Tolerance
COMPLETED · NA
-
A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI